8-K: DiaMedica Therapeutics Announces Full Year 2024 Financial Results and Business Update, Highlighting Progress in Stroke and Preeclampsia Programs

DiaMedica Therapeutics reports its full year 2024 financial results, provides a business update on its stroke and preeclampsia programs, and announces the appointment of Daniel J. O'Connor to the Board.

Summary

• DiaMedica Therapeutics Inc. provided a business update and announced financial results for the year ended December 31, 2024.
• The company is advancing its Acute Ischemic Stroke (AIS) program and expanding into preeclampsia treatment development.
• Dosing in the Phase 2 trial of DM199 for preeclampsia began in November 2024, with preliminary safety and efficacy data expected in the second quarter of 2025.
• The ReMEDy2 Phase 2/3 AIS trial has activated 30 hospitals, and an interim analysis on the first 200 participants is anticipated in the first half of 2026.
• The Data Safety Monitoring Board (DSMB) completed a safety review of the ReMEDy2 trial and recommended continuation without modification.
• Daniel J. O'Connor was appointed to DiaMedica's Board of Directors in February 2025.
• The company's cash, cash equivalents, and short-term investments were $44.1 million as of December 31, 2024.
• DiaMedica anticipates its cash runway will fund planned clinical studies and support operations into the third quarter of 2026.
• Net cash used in operating activities for 2024 was $22.1 million, compared to $18.7 million in 2023.
• Research and Development (R&D) expenses were $19.1 million for 2024, compared to $13.1 million in 2023.
• General and Administrative (G&A) expenses decreased to $7.6 million in 2024 from $8.2 million in 2023.
• Net loss for 2024 was $24.4 million, or $0.60 loss per share, compared to $19.4 million, or $0.60 loss per share, for 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is progress in clinical trials and a new board member, the increased net loss and delayed interim analysis temper the positive aspects.

Positives

• Dosing has begun in the Phase 2 trial of DM199 for preeclampsia.
• The ReMEDy2 Phase 2/3 AIS trial has reached 30 activated sites.
• The DSMB recommended the ReMEDy2 trial continue without modification.
• Experienced biotech executive Daniel J. O'Connor was appointed to the Board.
• The company has a cash runway into Q3 2026.

Negatives

• The interim analysis for the ReMEDy2 trial is delayed and now expected in the first half of 2026 due to slower than expected enrollment.
• Net loss increased to $24.4 million in 2024 from $19.4 million in 2023.
• Net cash used in operating activities increased to $22.1 million in 2024 from $18.7 million in 2023.

Risks

• The timing of the interim analysis for the ReMEDy2 trial is subject to enrollment rates.
• Clinical trial results may be unfavorable.
• The company's ability to obtain regulatory approval for DM199 is uncertain.
• The company relies on third parties to conduct clinical trials.
• The company's ability to continue to obtain funding for its operations is a risk.

Future Outlook

DiaMedica anticipates its current cash will fund planned clinical studies and support corporate operations into the third quarter of 2026. The company expects R&D expenses to increase moderately as it expands the ReMEDy2 trial and the DM199 clinical development program into preeclampsia.

Management Comments

• Rick Pauls, President and CEO of DiaMedica, stated that the company made significant progress in 2024, advancing their AIS program and expanding into preeclampsia.
• He noted that both populations are critically underserved, representing substantial unmet medical needs and large commercial opportunities.

Industry Context

DiaMedica is operating in the competitive biopharmaceutical industry, focusing on acute ischemic stroke and preeclampsia, areas with significant unmet medical needs. The company's progress in clinical trials and financial position will be closely watched by investors and competitors alike.

Comparison to Industry Standards

• DiaMedica's cash runway into Q3 2026 is a positive sign, but its increased net loss and R&D expenses are areas of concern.
• Compared to companies like Biohaven (acquired by Pfizer) which also focused on neurological disorders, DiaMedica is still in an earlier stage of development.
• Companies such as Momenta Pharmaceuticals (acquired by Johnson & Johnson) which focused on autoimmune diseases, provide a benchmark for successful clinical development and acquisition.
• The success of DM199 in clinical trials will be crucial for DiaMedica to compete with established treatments and companies in the stroke and preeclampsia markets.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and clinical trial progress will impact shareholder value.
• Employees: The company's financial stability and clinical development plans affect job security and opportunities.
• Patients: Successful development of DM199 could provide new treatment options for acute ischemic stroke and preeclampsia.

Next Steps

• Continue enrollment in the ReMEDy2 Phase 2/3 AIS trial.
• Advance the Phase 2 trial of DM199 for preeclampsia and report topline data in Q2 2025.
• Conduct the interim analysis for the ReMEDy2 trial in the first half of 2026.

Key Dates